ec5026
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 9, 2019 (NCT04228302)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Epoxide hydrolaseINHIBITOR
Epoxide hydrolase inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07142044 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2025 | EicOsis Human Health Inc., Michael J. Fox Foundation for Parkinson's Research, University of California, Davis |
| NCT06438471 | Phase 1 | Dec 31, 2024 | EicOsis Human Health Inc. |
| NCT06089837 | Phase 1 | Nov 15, 2023 | EicOsis Human Health Inc., New Zealand Clinical Research |
| NCT04908995 | Phase 1 | May 18, 2021 | EicOsis Human Health Inc. |
| NCT04228302 | Phase 1 | Dec 9, 2019 | EicOsis Human Health Inc., National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EicOsis Human Health Inc. | For profit | 5 | 5 | 2 | 2019 |
| Michael J. Fox Foundation for Parkinson's Research | Academic/Hospital | 1 | 0 | 1 | 2025 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2019 |
| New Zealand Clinical Research | For profit | 1 | 0 | 1 | 2023 |
| University of California, Davis | Academic/Hospital | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1